We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




World-First Angiogenesis Reversal Could Help Treat Tumors

By Biotechdaily staff writers
Posted on 12 May 2008
Researchers investigating how blood vessel growth keeps tumors alive have made a world-first discovery that could increase the chances of effectively treating life-threatening tumors. More...


Western Australian Institute for Medical Research (WAIMR; Perth) associate professor Dr. Ruth Ganss and her team discovered that a gene called RGS5 can reverse angiogenesis--the growth of blood vessels inside the tumor. This finding was published in the April 17, 2008, issue of the journal Nature.

"It's the uncontrolled growth of blood vessels and the formation of abnormal blood vessels inside tumors that ‘feed' them, allowing them to grow and stopping the immune system from wiping out the tumor,” said Dr. Ganss. "What we've shown is that RGS5 is a master gene in angiogenesis and that when it is removed, angiogenesis reverses and the blood vessels in tumors appear more normal. Importantly, this normalization changes the tumor environment in a way that improves immune cell entry, meaning tumors can be destroyed and improving survival rates in laboratory tests.”

Reversing abnormal vessel growth represents a fresh approach to tackling angiogenesis, with most current research focusing on how to block or kill tumor-feeding blood vessels.

"We've long-suspected this research would deliver advances in knowledge about what impacts tumor growth and this publication recognizes the innovation and importance of our work,” said Dr. Ganss. "By understanding what is actually going on in the tumor itself, the ultimate hope is that we'll be able to work on making current therapeutic approaches even more successful and reducing side effects of them.”

Earlier in April 2008, a second article by Dr. Ganss and her team was published in The Journal of Clinical Investigation that describes how tumors can be attacked by the immune system with fewer side effects. "This discovery involves targeting tumors with inflammatory substances that change the environment, so immune cells can attack the tumor through blood vessels more effectively and lessen the amount of toxins going elsewhere in the body,” she said.

WAIMR director Prof. Peter Klinken praised Dr. Ganss' team reported that their work was serving to further put WA on the scientific world map. "This breakthrough is one of the most significant discoveries to come out of WAIMR. The potential for this new knowledge to positively impact the lives of cancer patients in the future is very exciting,” he said. "The fact that this breakthrough has come during our 10-year anniversary celebrations is just fantastic.”


Related Links:
Western Australian Institute for Medical Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.